Will Prostatic Acid Phosphatase Determination by Radioimmunoassay Increase The Diagnosis of Early Prostatic Cancer?

No AccessJournal of Urology1 Mar 1981Will Prostatic Acid Phosphatase Determination by Radioimmunoassay Increase The Diagnosis of Early Prostatic Cancer? Gordon R. Quinones, J. Rohner Thomas, Joseph R. Drago, and Laurence M. Demers Gordon R. QuinonesGordon R. Quinones More articles by this author , J. Rohner ThomasJ. Rohner Thomas More articles by this author , Joseph R. DragoJoseph R. Drago More articles by this author , and Laurence M. DemersLaurence M. Demers More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)55037-5AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail The determination of serum prostatic acid phosphatase by radioimmunoassay has received considerable attention as a more sensitive and specific test than its measurement by the usual enzymatic assay. It has been suggested that the increased sensitivity of the radioimmunoassay will improve greatly our ability to diagnose prostatic cancer in the early operative stages. Our study compares prostatic acid phosphatase determination by the radioimmunoassay and enzymatic techniques in 56 untreated and treated patients with prostatic cancer. In addition, 22 patients with biopsy-proved benign prostatic hyperplasia also were studied. The radioimmunoassay used was based on antibodies raised against prostatic acid phosphatase highly purified by 2-stage, ion-specific chromatography and isoelectric focusing techniques. The enzymatic assay used thymolphthalein monophosphate as the substrate. The patients were staged on the basis of digital examination, technetium bone scan and pelvic lymphadenectomy. There were 4 patients with stage A, 12 with stage B, 13 with stage C and 27 with stage D disease. The radioimmunoassay showed an elevated prostatic acid phosphatase in 13 per cent of the patients with intracapsular disease (stages A and B) and in 50 per cent of the patients with extracapsular disease (stages C and D). This finding compares with an enzymatic prostatic acid phosphatase elevation in 13 per cent of the patients with intracapsular and 53 per cent of those with extracapsular disease. There were fewer falsely elevated prostatic acid phosphatase levels by radioimmunoassay (2) than by enzymatic assay (6) in the patients with benign prostatic hyperplasia. Our data show that the radioimmunoassay method provides a reliable and specific measurement of prostatic acid phosphatase. However, the radioimmunoassay measurement of prostatic acid phosphatase does not appear to be more effective as a screening aid in the diagnosis of early stages of prostatic cancer and in our study it was no more helpful than the enzymatic assay. © 1981 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byRobey E, Schellhammer P, Wright G and El-mahdi A (2018) Cancer Serum Index and Prostatic Acid Phosphatase for Detection of Progressive Prostatic CancerJournal of Urology, VOL. 134, NO. 4, (787-790), Online publication date: 1-Oct-1985.Vihko P, Kontturi M, Lukkarinen O and Vihko R (2018) Immunoreactive Prostatic Acid Phosphatase Inprostatic Cancer: Diagnosis and Followup of PatientsJournal of Urology, VOL. 133, NO. 6, (979-982), Online publication date: 1-Jun-1985.Pontes J (2018) Biological Markers in Prostate CancerJournal of Urology, VOL. 130, NO. 6, (1037-1047), Online publication date: 1-Dec-1983.Hopkins S, Nissenkorn I, Palmieri G, Ikard M, Moinuddin M and Soloway M (2018) Serial Spot Hydroxyproline/Creatinine Ratios in Metastatic Prostatic CancerJournal of Urology, VOL. 129, NO. 2, (319-323), Online publication date: 1-Feb-1983.Fleischmann J, Catalona W, Fair W, Heston W and Menon M (2018) Lack of Value of Radioimmunoassay for Prostatic Acid Phosphatase as a Screening Test for Prostatic Cancer in Patients with Obstructive Prostatic HyperplasiaJournal of Urology, VOL. 129, NO. 2, (312-314), Online publication date: 1-Feb-1983.Pontes J (2018) Editorial CommentsJournal of Urology, VOL. 128, NO. 6, (1215-1215), Online publication date: 1-Dec-1982.Bruce A (2018) Editorial CommentsJournal of Urology, VOL. 128, NO. 6, (1215-1215), Online publication date: 1-Dec-1982.Van Cangh P, Opsomer R and De Nayer P (2018) Serum Prostatic Acid Phosphatase Determination in Prostatic Diseases: A Critical Comparison of an Enzymatic and a Radioimmunologic AssayJournal of Urology, VOL. 128, NO. 6, (1212-1215), Online publication date: 1-Dec-1982.Olsson C (2018) Editorial CommentJournal of Urology, VOL. 128, NO. 4, (738-738), Online publication date: 1-Oct-1982.Fair W, Heston W, Kabmon D, Crane D, Catalona W, Ladenson J, McDonald J, Noll B and Harvey G (2018) Prostatic Cancer, Acid Phosphatase, Creatine Kinase-Bb and Race: A Prospective StudyJournal of Urology, VOL. 128, NO. 4, (735-738), Online publication date: 1-Oct-1982. Volume 125Issue 3March 1981Page: 361-364 Advertisement Copyright & Permissions© 1981 by The American Urological Association Education and Research, Inc.MetricsAuthor Information Gordon R. Quinones More articles by this author J. Rohner Thomas More articles by this author Joseph R. Drago More articles by this author Laurence M. Demers More articles by this author Expand All Advertisement PDF downloadLoading ...